CVS Health has announced the appointment of longtime executive David Joyner as its new CEO, replacing Karen Lynch as the company grapples with declining profits and a steep drop in its stock price.
The change, effective immediately, comes as CVS attempts to regain footing amid financial strain in its insurance and retail pharmacy sectors.
CVS shares have plunged nearly 20 percent this year, and the company has slashed its profit guidance three times in 2024.
Alongside the CEO transition, CVS confirmed on Friday it anticipates higher medical costs for its insurance unit, Aetna, and struggles with reduced consumer spending in its retail pharmacy business.
These factors have added pressure on the company, which is also contending with reimbursement challenges related to prescription drugs.
David Joyner’s Return to Lead CVS
Joyner, who previously retired from CVS in 2019, returned to the company in 2023 to lead Caremark, its pharmacy benefits management (PBM) division.
With extensive experience in the pharmacy and insurance industries, Joyner is seen as a steady hand to guide the company through turbulent times.
He began his career at Aetna and has held senior roles at both CVS and Caremark, including executive vice president of sales and marketing.
He said:
“I came back to CVS Health in 2023 because I believed I could give more to the company, and I take this opportunity today for the same reason.”
Glenview Capital’s Push for Change
The leadership change comes just weeks after Glenview Capital, a major CVS shareholder, pushed for a reshuffle at the company.
The firm expressed support for Lynch’s departure, calling for a refreshed board of directors to help strengthen the company’s governance and culture.
CVS’s board had also reportedly been exploring strategic options, including a potential breakup of its insurance and retail divisions. However, CVS stated on Friday that it would remain intact moving forward.
Financial Struggles and Operational Challenges
CVS’s financial troubles stem largely from rising medical costs and soft consumer spending.
The company has been hit hard by elevated medical expenses in its Medicare Advantage plans as more seniors return to hospitals for procedures that were postponed during the COVID-19 pandemic.
CVS expects its insurance unit’s medical benefit ratio (MBR)—a key metric that compares medical expenses to premiums—to rise to 95.2 percent in the third quarter, up from 85.7 percent the previous year.
This increase reflects higher payouts relative to premiums, which has hurt profitability.
CVS has also forecast adjusted earnings of between $1.05 and $1.10 per share for the third quarter. The company will officially report its third-quarter earnings on November 6.
Need Career Advice? Get employment skills advice at all levels of your career
Joyner’s Challenges: Navigating Regulatory Scrutiny and Rising Costs
As CEO, Joyner will need to address not only the company’s financial woes but also the increasing regulatory scrutiny of PBMs like Caremark.
In recent months, the Federal Trade Commission (FTC) has taken legal action against Caremark and other PBMs, accusing them of engaging in practices that inflate costs for patients, particularly for life-saving medications like insulin.
Additionally, Joyner will face continued pressure to reduce medical costs in CVS’s health insurance segment while improving margins in its Medicare Advantage business.
In August, CVS executives expressed a goal of achieving a 100 to 200 basis point margin improvement in Medicare Advantage by next year.
What Lies Ahead for CVS Under Joyner’s Leadership
The transition to Joyner as CEO marks a pivotal moment for CVS Health as the company works to address rising medical costs, increasing regulatory pressures, and a struggling stock price.
While Lynch’s departure signals a shift in leadership, it remains to be seen whether Joyner can steer the company toward improved financial performance and stabilize its stock price, which fell another 5 percent after the announcement on Friday.
As CVS moves forward with Joyner at the helm, the company will need to strike a delicate balance between cutting costs, maintaining its operations, and navigating a challenging regulatory landscape.
For investors, all eyes will be on CVS’s third-quarter earnings report in early November to see if the company’s strategic changes will start yielding positive results.
